Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAASFLEX dapagliflozin crossover study in prediabetes
NL-OMON55824Phase 4Active, not recruiting
- Sponsor
- Maastricht University
- Start
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of dapagliflozin in prediabetes and impaired glucose homeostasis (2 arms), sponsored by Maastricht University. Primary endpoint: Nightly substrate oxidation. Started Sep 2019; status: active, not recruiting.
02
Drugs
dapagliflozin
03
Conditions
prediabetesimpaired glucose homeostasis
Beyond the preview
Go deeper on NL-OMON55824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55824.